IRIS
CASADEI GARDINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.889
AS - Asia 5.358
NA - Nord America 4.434
SA - Sud America 1.464
AF - Africa 120
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 17.278
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.223
RU - Federazione Russa 3.614
SG - Singapore 2.073
CN - Cina 1.503
BR - Brasile 1.177
HK - Hong Kong 662
VN - Vietnam 632
IT - Italia 530
SE - Svezia 495
FR - Francia 294
RO - Romania 267
DE - Germania 199
GB - Regno Unito 144
AR - Argentina 125
IN - India 111
CA - Canada 102
MX - Messico 77
BD - Bangladesh 72
NL - Olanda 71
FI - Finlandia 56
PL - Polonia 50
ZA - Sudafrica 50
ID - Indonesia 49
AT - Austria 48
JP - Giappone 47
EC - Ecuador 44
TR - Turchia 35
ES - Italia 34
IQ - Iraq 33
CO - Colombia 30
VE - Venezuela 23
CL - Cile 21
MA - Marocco 20
LT - Lituania 18
PY - Paraguay 18
IE - Irlanda 14
UA - Ucraina 14
UZ - Uzbekistan 14
SA - Arabia Saudita 13
AE - Emirati Arabi Uniti 12
EG - Egitto 12
PH - Filippine 12
DZ - Algeria 11
PK - Pakistan 11
AZ - Azerbaigian 10
UY - Uruguay 9
IR - Iran 8
BO - Bolivia 7
KE - Kenya 7
MY - Malesia 7
PE - Perù 7
BE - Belgio 6
NP - Nepal 6
OM - Oman 6
TW - Taiwan 6
AU - Australia 5
BA - Bosnia-Erzegovina 5
HN - Honduras 5
IL - Israele 5
KZ - Kazakistan 5
NI - Nicaragua 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
AO - Angola 4
CH - Svizzera 4
EU - Europa 4
KG - Kirghizistan 4
LB - Libano 4
BG - Bulgaria 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HR - Croazia 3
JO - Giordania 3
MD - Moldavia 3
PA - Panama 3
SI - Slovenia 3
TH - Thailandia 3
A1 - Anonimo 2
AL - Albania 2
BB - Barbados 2
BH - Bahrain 2
BY - Bielorussia 2
CG - Congo 2
CI - Costa d'Avorio 2
ET - Etiopia 2
GR - Grecia 2
GT - Guatemala 2
JM - Giamaica 2
KR - Corea 2
KW - Kuwait 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
SR - Suriname 2
XK - ???statistics.table.value.countryCode.XK??? 2
BM - Bermuda 1
BW - Botswana 1
CM - Camerun 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
Totale 17.267
Salva come PNG Salva come JPEG
Città #
Dallas 1.532
Singapore 1.075
Moscow 767
Hong Kong 655
Ashburn 459
San Jose 357
New York 300
Beijing 288
Ho Chi Minh City 244
Shanghai 244
Lauterbourg 232
Hefei 220
Lawrence 149
Princeton 149
Los Angeles 125
Hanoi 121
Milan 107
São Paulo 99
Orem 63
Boardman 56
Santa Clara 56
Rome 51
Nuremberg 50
Montreal 44
Warsaw 43
London 41
Tokyo 41
Rio de Janeiro 40
Helsinki 39
Munich 34
Da Nang 33
Council Bluffs 32
Guangzhou 32
Poplar 32
Belo Horizonte 31
Stockholm 31
Denver 30
Vienna 30
Mexico City 29
Brooklyn 28
Atlanta 27
Cesano Boscone 26
Chennai 26
Porto Alegre 26
Johannesburg 25
Frankfurt am Main 24
Haiphong 23
Houston 23
Phoenix 23
Chicago 22
Amsterdam 21
Biên Hòa 21
Manchester 21
Brasília 20
Guarulhos 20
Toronto 20
Ankara 18
Curitiba 18
Shenzhen 18
Mumbai 17
Dhaka 16
Lappeenranta 16
Naples 15
Quito 14
Romagnano Sesia 14
Tashkent 14
Boston 13
New Delhi 13
Tianjin 13
Baghdad 12
Dublin 12
Hải Dương 12
Querétaro 12
Seattle 12
Bologna 11
Brescia 11
Buenos Aires 11
Can Tho 11
Guayaquil 11
Salvador 11
San Francisco 11
Thái Nguyên 11
Baku 10
Cape Town 10
Recife 10
The Dalles 10
Thái Bình 10
Campinas 9
Hanover 9
Jakarta 9
Montevideo 9
Phủ Lý 9
Santo André 9
Bắc Giang 8
Bắc Ninh 8
Charlotte 8
Honolulu 8
Monza 8
Philadelphia 8
Sumaré 8
Totale 8.864
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 424
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 417
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments 396
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 343
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 140
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 115
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 115
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 112
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 111
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 110
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 109
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 108
Correction to: Prospective minimally invasive pancreatic resections from the IGOMIPS registry: a snapshot of daily practice in Italy on 1191 between 2019 and 2022 (Updates in Surgery, (2023), 75, 6, (1439-1456), 10.1007/s13304-023-01592-7) 108
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 108
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 105
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 103
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 103
Comparing Liver Venous Deprivation and Portal Vein Embolization for Perihilar Cholangiocarcinoma: Is It Time to Shift the Focus to Hepatic Functional Reserve Rather than Hypertrophy? 102
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 102
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 101
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 101
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 97
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 96
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 96
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 96
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 95
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 94
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 93
Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma 92
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 92
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 91
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 91
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 91
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 91
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 90
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 90
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 89
Defining and predicting textbook outcomes for perihilar cholangiocarcinoma: analysis of factors improving achievement of desired postoperative outcomes 87
Cholangiocarcinoma: new perspectives for new horizons 87
Angiogenesis in biliary tract cancer: targeting and therapeutic potential 86
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 86
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments 86
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 86
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 85
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 84
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 84
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 84
EUS-GUIDED GASTROENTEROSTOMY FOR MANAGEMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A PROSPECTIVE SERIES FROM THE PROTECT REGISTRY 83
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 83
Mismatch repair deficiency as prognostic factor for stage III small bowel adenocarcinoma: A multicentric international study 82
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 82
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 81
Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review 81
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 81
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 80
Minimally Invasive Approach Provides Oncological Benefit in Patients with High Risk of Very Early Recurrence (VER) After Surgery for Intrahepatic Cholangiocarcinoma (iCCA) 79
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 79
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 78
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 78
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 77
Correction: Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 77
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming 77
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 77
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 76
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 75
Over-the-Wire Lumen-Apposing Metal Stent Exchange for Management of a Long-Term Choledochoduodenostomy Dysfunction 75
Sorafenib for the treatment of unresectable hepatocellular carcinoma: Preliminary toxicity and activity data in dogs 74
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 73
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 72
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 72
BRAF-mutated colorectal cancer: Clinical and molecular insights 72
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials 71
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 70
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 70
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 70
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 69
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 69
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 69
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 68
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 68
Platelets and hepatocellular cancer: Bridging the bench to the clinics 68
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 68
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 66
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 66
A Clinicopathologic Comparison Between Early-Onset and Late-Onset Small Bowel Adenocarcinoma: A Multicenter International Study 66
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 65
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 65
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 65
The prognostic value of the new combined hemo-eosinophil inflammation index (Hei index): A multicenter analysis of anal cancer patients treated with concurrent chemo-radiation 65
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions 64
Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison 64
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 63
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 63
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 63
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study 63
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 63
ROS1 rearrangements are uncommon in biliary tract cancers 63
The Italian Rare Pancreatic Exocrine Cancer Initiative 63
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 62
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib 62
Totale 9.547
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.436
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.436
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022100 0 0 0 40 2 5 15 22 6 2 0 8
2022/2023842 325 171 70 12 2 123 25 46 49 5 6 8
2023/2024673 35 18 58 54 33 226 75 47 0 11 30 86
2024/20253.046 349 70 73 33 67 254 687 289 397 281 193 353
2025/202612.970 935 1.392 1.551 1.888 1.027 433 958 947 3.362 477 0 0
Totale 17.761